Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital System
The race-adjusted estimated glomerular filtration rate reduced Black patients’ access to kidney transplants. NYC Health+Hospitals is studying the effect of a race-neutral algorithm PerspectiveEfforts toward Equity Share on Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action...
Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study
AbstractBackground In patients with EGFR-mutant non–small cell lung cancer (NSCLC), leptomeningeal metastasis (LM) following progression on third-generation EGFR tyrosine kinase inhibitors (TKIs) remains a life-threatening complication. Methods In this ambispective cohort study, we included 21 patients with LM who progressed...
Downregulation of B7-H4 contributes to the synergistic effect of USP2a-targeted/anti-PD-1 combination therapy in EGFR mutant lung cancer
Abstract Anti-PD-1 treatment has shown clinical benefit in malignant cancers. However, EGFR-mutant (EGFR-MT) lung adenocarcinoma, an immune-cold tumor, shows poor response to this immunotherapy. This scenario is associated with elevated levels of B7-H4, an immune checkpoint demonstrating CD8+ T cell...
Osimertinib Plus Chemotherapy Improves Outcomes in EGFR/TP53 mutant NSCLC: The TOP Study
Osimertinib Plus Chemotherapy Improves Outcomes in EGFR/TP53 mutant NSCLC: The TOP Study The treatment landscape of EGFR-mutant NSCLC has evolved significantly with the introduction of third-generation EGFR tyrosine kinase inhibitors such as osimertinib. However, not all patients derive the same...
Case Report: SMARCA4-deficient non-small cell lung cancer - effective local control with radiotherapy and emergence of a targetable EGFR mutation
BackgroundSMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) represents a distinct, highly aggressive molecular subtype associated with a poor pro Abstract Background: SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) represents a distinct, highly aggressive molecular subtype associated with a poor prognosis. While immune...
Risk of high-grade infections in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a meta-analysis of randomized controlled trials
BackgroundAlthough anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab are extensively used in metastatic colorectal Abstract Background: Although anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab are extensively used in metastatic colorectal cancer therapy, their association...
BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data
AbstractBackground Drug resistance and lack of predicting biomarkers are a major challenge for cancer therapy. The combination of a BRAF inhibitor (BRAFi) together with an anti-EGFR inhibitor (EGFRi) represents a standard of care approach in BRAFV600E metastatic colorectal cancer (mCRC)...
TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations
Background Activating mutations in the epidermal growth factor receptor (EGFR), particularly exon 19 deletions and L858R mutation, are frequently observed in non-small cell lung cancer (NSCLC) and confer sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Among these EGFR-TKIs, osimertinib is currently...